



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 25 Apr 2022 (#16)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- **Urgent: Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office)** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
 - FMHS contact: cdevries@sun.ac.za
 - Stellenbosch Campus contact lizelk@sun.ac.za.

Link to the training: https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html

- **NOT-CA-22-081 Notice of Pre-application Webinar for NCI Funding Opportunity Announcements for Cancer Epidemiology Cohorts** ([PAR-22-161](#), [PAR-22-162](#)) The National Cancer Institute's (NCI) Division of Cancer Control and Population Sciences (DCCPS) invites applications from investigators for cancer epidemiology cohorts through two recently published Funding Opportunity Announcements (FOAs). NCI will hold one pre-application webinar covering the two FOAs. The pre-application webinar, to be held on **April 27th, from 1:00 pm - 2:00 pm EDT**, will include an overview of each funding opportunity and specific requirements for each. The webinar will conclude with a final, open question and answer session. This webinar will be recorded for anyone not able to make the live event and made available approximately two weeks following the live event on <https://epi.grants.cancer.gov/cohorts/>. *Registration for the webinar is required. Register and learn more [here](#).*
- **NOT-OD-22-115 Findings of Research Misconduct.**

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notices of Special Interest

- [NOT-HD-22-003](#) **Notice of Special Interest (NOSI) - Administrative Supplements for Research of Emerging and Existing Issues of COVID-19 Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities.** The purpose of this funding opportunity is to provide an opportunity for funded researchers in these various fields to pursue supplemental funding to conduct research addressing these emerging and other existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. The goal of this NOSI is to not replace or to compete with the various COVID-related funding opportunities currently available. Instead, the purpose is to complement them by offering a funding opportunity for currently funded investigators to address key issues not currently covered by available COVID-related funding announcements among these populations. This NOSI is encouraging the submission of applications to support research on the SARS-CoV-2 virus and the associated COVID-19 pandemic that address the following areas of interest including, but not limited to:
 - Menstrual Health, Fertility, Pregnancy and Perinatal Issues
 - Vaccination Studies
 - Pharmacology Issues
 - Developmental and Schooling Impacts
 - Testing Studies
 - Mental Health Concerns
 - Viral Strains and Other Viral Issues
 - Viral Co-Infections
 - Pandemic Effects
 - Neurological effects

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: [PA-20-272](#) - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). Requests may be for one year of support only. The Research Strategy section of the application is limited to 6 pages. Requests may be for one year of support only. The Research Strategy section of the application is limited to 6 pages. Applicants may request administrative supplement applications with budgets exceeding the parent award for COVID-19 and other Public Health Emergency research. Budgets must be reasonable and reflect the actual needs of the project. Individual Institutes/Centers may have their own specific guidance and limits for the funding of these supplements. Applicants may request administrative supplement applications with budgets exceeding the parent award for COVID-19 and other Public Health Emergency research. Budgets must be reasonable and reflect the actual needs of the project. Individual Institutes/Centers may have their own specific guidance and limits for the funding of these supplements.

Funding Opportunity Announcements (FOA)

1. National Institute of Neurological Disorders and Stroke ([NINDS](#)) Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-142](#)

Type: UG3/UH3

Application Due Date: June 22, 2022 through to Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All Phase 1 exploratory trials must contribute to the justification for and provide some of the data required to inform a future Phase 2 trial that may also be performed as part of the current grant application, should the results of the Phase 1 studies be encouraging. This FOA uses the UG3/UH3 mechanism.

Budget:

2. Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-151](#) reissue **Type:** D43 of PAR-19-283.

Application Due Date: August 22, 2022; August 22, 2023; August 22, 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country. This FOA can support training for conducting research in a broad range of HIV research areas across HIV prevention, treatment, care, and quality of life continuum. This includes basic, epidemiologic, clinical, behavioral and social sciences, data science, community-based, implementation, operations, health services, and health systems research. Cross-disciplinary research as well as HIV associated comorbidities and coinfections affecting the HIV epidemic will be supported under this FOA. An application should focus the proposed training program to strengthen research capacity in a defined high priority HIV scientific area aligned with NIH HIV/AIDS research priorities ([NOT-OD-20-018](#)) at a specific LMIC institution and collaborating LMIC partner institutions. This FOA allows qualified Trainees to serve as the lead investigator of an independent clinical trial; or to propose a separate ancillary study to an existing trial under the mentorship of an appropriate clinical researcher or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: Application budgets are limited to \$280,000 in direct costs per year exclusive of consortium indirect costs. The maximum project period is 5 years.

3. Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-152](#) Reissue **Type:** D71 of PAR-19-284

Application Due Date: August 22, 2022; August 22, 2023; August 22, 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The Fogarty HIV Research Training (HIVRT) Program supports research training that strengthens HIV research capacity of institutions in low- and middle-income countries (LMICs). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Budget: Application budgets are limited to \$28,000 direct costs per year exclusive of consortium indirect costs. The maximum project period is 2 years.

4. Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-153](#) Reissue **Type:** G11 of PAR-19-285

Application Due Date: August 22, 2022; August 22, 2023; August 22, 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overall goal of the Fogarty HIV Research Training (HIVRT) Program is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) by enhancing the functional resources required to conduct HIV research on the evolving HIV epidemic in their countries. This Funding Opportunity Announcement (FOA) encourages collaborative applications from U.S. and LMIC institutions to develop training programs to achieve technical, administrative, and financial management expertise required for one of several research infrastructure support functions considered critical to a successful high-quality research environment. These are: a) research administration and management, b) research integrity oversight, c) ethical review of research for the protection of human subjects, d) laboratory animal welfare oversight, e) advanced laboratory instrument services, f) health sciences library and information services, g) information and communications technology systems (ICT) for research, h) biostatistics and data analysis, i) technology transfer and intellectual property protection, j) harassment and discrimination policy and prevention and k) any area not mentioned above that justifiably will contribute to enhancing Institutional services that can support research activities. Training programs to support research infrastructure will maximize previous investments, further strengthen the LMIC institution's research capabilities, and potentially provide more accessible research infrastructure training opportunities to others at Institutions in their own country and in other LMICs.

Budget: Application budgets are limited to \$94,000 direct costs per year exclusive of consortium indirect costs. Indirect Costs (also known as Facilities & Administrative [F&A] Costs) are reimbursed at 8% of modified total direct costs (exclusive of tuition and fees, consortium costs in excess of \$25,000, and expenditures for equipment), rather than on the basis of a negotiated rate agreement. The Indirect Cost limitation applies to direct awards and to subcontracts. Awards may support travel for trainees to participate in appropriate training experiences at other institutions or to attend scientific meetings and workshops that the training program determines to be necessary. Awards may support travel for trainees to present training-related research results at conferences and meetings. Funds may be requested for lodging and per diem at other institutions for short-term trainees.

5. Neuronal Vulnerability to Proteinopathies in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-23-028](#)

Type: R01

Application Due Date: July 15, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to define and characterize neuronal and glial cell populations that are vulnerable to Alzheimer's disease (AD) and AD-related dementias (ADRD) proteinopathies.

Budget: NIA intends to commit \$8 million in fiscal year 2023 to fund 8-10 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-NS-22-052](#)

Type: U19

Application Due Date: June 09, 2022; October 11, 2022; June 09, 2023; October 10, 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development. Discovery and validation of pharmacodynamic markers as well as development and validation of animal models or outcome measures are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the five years of the award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound and well-validated assays. If the data does not currently exist, the application must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, obstetric pain, gynecologic pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. Projects to develop analgesics for a combination of chronic overlapping pain conditions or for specific disease or pathological conditions will also be considered. Projects that seek to identify pain treatment targets in specific populations such as women, children, older adults, and other underrepresented groups will also be responsive to this FOA. Input from patients and caregivers on the therapeutic goals of the project is highly encouraged.

Budget: NIH intends to fund an estimate of 3-6 awards, for fiscal year 2023. Future year amounts will depend on annual appropriations. Application budgets are limited to direct costs of \$1.5 million per year. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizel*
e: lizelk@sun.ac.za | t: +27 21 808 2105